Improving clinical trials
We believe clinical trials can work better, so we're bringing the right people together to make trials faster, cheaper and more likely to succeed.
Slice title
The Critical Path for Parkinson's
Our Director of Research, Dr Arthur Roach, explains more about this exciting and essential initiative.
What is the Critical Path for Parkinson's?
Clinical trials are the most costly and lengthy part of the whole research process. In recent years, several promising new treatments for Parkinson's have failed to show benefit in clinical trials.
Many in the research community believe the problem may not be that the drugs don't work, but that we're testing them in the wrong way.
That's why we fund and lead the Critical Path for Parkinson's.
This international collaboration brings together pharmaceutical companies, regulatory agencies, universities and charities to share data from major studies and trials.
Our expert partner - the Critical Path Institute - is using this data to develop new tools and strategies to improve clinical trials for Parkinson's.
This ambitious collaboration aims to change the way clinical trials are carried out, and help ensure new treatments reach people with Parkinson's faster.
Read more about the Critical Path for Parkinson's initiative on our research blog.
Meet our expert partners: Critical Path Institute
Critical Path Institute is an independent non-profit dedicated to bringing scientists together to collaborate and improve the drug development process.
Slice title
Latest news
The Critical Path for Parkinson's programme has recently published an open-access review paper in the Journal of Parkinson's Disease. The paper highlights the EMA qualification of DaT imaging to select people taking part in clinical trials looking at early-stage Parkinson's.
This year's members' meeting attracted a record 99 attendees from several countries, including leaders from major pharmaceutical companies. They were all united in the goal to improve clinical trials.
The Critical Path for Parkinson's has delivered a new tool in the search for new Parkinson's treatments - a brain scan that can be used to select the right people for clinical trials.